1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. INHIBRX INC

Inhibrx Inc XNAS: INBX

Inhibrx Inc Live Share Price Today, Share Analysis and Chart

Download real time

14.72 0.37 (2.58%)

58.44% Fall from 52W High

109.8K XNAS Volume

XNAS 24 Mar, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share

Inhibrx Inc Key Metrics

Default

Market Capitalization

Below industry Median
697.4

PE TTM

Negative PE TTM
-2.6

Price to Book

High in industry
17.7

Institutional holding current Qtr %

Below industry Median
70.5

Revenue Growth Qtr YoY %

Negative Revenue Growth Qtr YoY %
-100

Operating Revenue growth TTM %

Below industry Median
39.3

Net Profit Qtr Growth YoY %

Negative Net Profit Qtr Growth YoY %
-60.9

Net Profit TTM Growth %

Negative Net Profit TTM Growth %
-66.5

Operating Profit Margin TTM %

Negative Operating Profit Margin TTM %
-13,980.9

Piotroski Score

Below industry Median
2

Rel Perf vs Sector quarter%

-7.1

ROE Annual %

Negative ROE Annual %
-475.3

RoA Annual %

Negative RoA Annual %
-80.6
All financials are in USD Million and price data in USD
VIEW MORE

13

S

14

W

0

O

3

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Inhibrx Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Dec '22Dec '23Dec '24Dec '2502.55Actual RevenueAvg. Estimate
Inline

Inhibrx Inc's Revenue was higher than average estimate 1 time in past 2 years

EPS forecast

Current EPS
-5.1
Avg. Estimate
104.9
Low Estimate
104.9
High Estimate
104.9
Current EPS
Avg. Estimate
Hit

EPS is expected to grow by 2148.4% in FY24

Consensus Recommendation

2 ANALYST Recommendations
HOLD

Created with Highcharts 7.2.22Hold

The consensus recommendation from 2 analysts for Inhibrx Inc is HOLD

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Inhibrx Inc Stock Analysis

Inhibrx Inc stock analysis with key metrics, changes, and trends.

Inhibrx Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$1.8 M17.36%negative

Annual Revenue fell 17.36%, in the last year to $1.8 M. Its sector's average revenue growth for the last fiscal year was 7.46%.

Annual Net Profit$241.36 M66.2%negative

Annual Net Profit fell 66.2% in the last year to $241.36 M. Its sector's average net profit growth for the last fiscal year was -32.46%.

Price to Earning Ratio-2.57-negative

Price to Earning Ratio is -2.57, which is negative.

Stock Price$14.72-57.81%negative

Stock Price fell 57.81% and underperformed its sector by 67.71% in the past year.

Quarterly Net profit$78.71 M60.91%negative

Quarterly Net profit fell 60.91% YoY to $78.71 M. Its sector's average net profit growth YoY for the quarter was -47.25%.

Debt to Equity Ratio4.83-negative

Debt to Equity Ratio of 4.83 is higher than 1. This implies that company assets are financed through debt.

Return on Equity(ROE)-475.31 %-475.31%negative

Return on Equity(ROE) for the last financial year was -475.31%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding22.01 %-2.19%negative

Mutual Fund Holding decreased by 2.19% in the last quarter to 22.01.

Interest Coverage Ratio-6.53-negative

Interest Coverage Ratio is -6.53, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding70.52 %-8.08%negative

Institutional Holding decreased by 8.08% in the last quarter to 70.52.

VIEW LESS


Loading data..

Inhibrx Inc - Company Profile

What does Inhibrx Inc do?

Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.

Inhibrx Inc Management structure

All Gross Remunerations are in USD
Mr. Mark Paul Lappe
Chairman of the Board, President and Chief Executive Officer
-
2023
Gross Remuneration
Year
Dr. Brendan P. Eckelman, PhD
Chief Scientific Officer
-
2023
Gross Remuneration
Year
Ms. Kelly D. Deck, C.P.A.
Chief Financial Officer and Principal Accounting Officer
-
2023
Gross Remuneration
Year

Inhibrx Inc Board of directors

All Gross Remunerations are in USD
Ms. Kimberly J. Manhard
Independent Director
-
2023
Gross Remuneration
Year
Dr. Jon Faiz Kayyem
Independent Director
-
2023
Gross Remuneration
Year
Mr. Mark Paul Lappe
Chairman of the Board, President and Chief Executi
-
2023
Gross Remuneration
Year
Dr. Kristiina Vuori, M.D.,PhD
Independent Director
-
2023
Gross Remuneration
Year
Mr. Douglas G. Forsyth
Independent Director
-
2023
Gross Remuneration
Year

Inhibrx Inc FAQ

How is Inhibrx Inc today?
Inhibrx Inc today is trading in the green, and is up by 2.58% at 14.72.
Inhibrx Inc is currently trading up 2.58% on an intraday basis. In the past week the stock rose 4.40%. stock has been up 0.14% in the past quarter and fell -57.81% in the past year. You can view this in the overview section.